Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines

Chemico-Biological Interactions

Volumn 181, Issue 2, 2009, Pages 185-192

  Lee, Sun Joo ^a   Kim, Yun Jeong ^b   Lee, Chung Soo ^b   Bae, Jaeman ^a  

^a Konkuk University Hospital   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Apoptotic proteins; Camptothecin; Cell death; Epithelial ovarian cancer cell lines; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CASPASE 3; CYTOCHROME C; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DRUG POTENTIATION; ENZYME ACTIVATION; EPITHELIUM CELL; GROWTH INHIBITION; NONHUMAN; OVARY CARCINOMA; PROTEIN CLEAVAGE; RAT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; DNA DAMAGE; ENZYME ACTIVATORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUANYLATE CYCLASE; HUMANS; INDAZOLES; NEOPLASM PROTEINS; OVARIAN NEOPLASMS;

EID: 68849102152     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.05.013     Document Type: Article

References (41)

1. Arbuck S.G., and Takimoto C.H. An overview of topoisomerase I-targeting agents. Semin. Hematol. 35 (1998) 3-12
2. Ackermann S., Beckmann M.W., Thiel F., and Bogenrieder T. Topotecan in cervical cancer. Int. J. Gynecol. Cancer 17 (2007) 1215-1223
3. Porter S.E., and Champoux J.J. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res. 17 (1989) 8521-8532
4. Nitiss J.L., and Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol. 50 (1996) 1095-1102
5. Tsao Y.P., Russo A., Nyamuswa G., Silber R., and Liu L.F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 53 (1993) 5908-5914
6. Shao R.G., Cao C.X., Zhang H., Kohn K.W., Wold M.S., and Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 18 (1999) 1397-1406
7. Wenzel U., Nickel A., Kuntz S., and Daniel H. Ascorbic acid suppresses drug-induced apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Carcinogenesis 25 (2004) 703-712
8. Xia S., Rosen E.M., and Laterra J. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress. Cancer Res. 65 (2005) 5248-5255
9. Ferreira C.G., Span S.W., Peters G.J., Kruyt F.A., and Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 60 (2000) 7133-7141
10. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
11. Albihn A., Mo H., Yang Y., and Henriksson M. Camptothecin-induced apoptosis is enhanced by Myc and involves PKCδ signaling. Int. J. Cancer 121 (2007) 1821-1829
12. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., and Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 116 (1995) 1973-1978
13. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., and Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
14. Pan S.L., Guh J.H., Peng C.Y., Wang S.W., Chang Y.L., Cheng F.C., Chang J.H., Kuo S.C., Lee F.Y., and Teng C.M. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J. Pharmacol. Exp. Ther. 314 (2005) 35-42
15. Zhao Q., Du J., Gu H., Teng X., Zhang Q., Qin H., and Liu N. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas 34 (2007) 242-247
16. Chen C.J., Hsu M.H., Huang L.J., Yamori T., Chung J.G., Lee F.Y., Teng C.M., and Kuo S.C. Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem. Pharmacol. 75 (2008) 360-368
17. 1 in human hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 312 (2005) 917-925
18. Lau C.K., Yang Z.F., Lam S.P., Lam C.T., Ngai P., Tam K.H., Poon R.T., and Fan S.T. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol. Ther. 6 (2007) 1900-1907
19. Yeo E.J., Ryu J.H., Chun Y.S., Cho Y.S., Jang I.J., Cho H., Kim J., Kim M.S., and Park J.W. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res. 66 (2006) 6345-6352
20. Liu Y.N., Pan S.L., Peng C.Y., Huang D.Y., Guh J.H., Kuo S.C., Lee F.Y., and Teng C.M. YC-1 induces heat shock protein 70 expression and prevents oxidized LDL-mediated apoptosis in vascular smooth muscle cells. Shock 30 (2008) 274-279
21. + channel inhibition. Mol. Pharmacol. 61 (2002) 97-104
22. Högberg T., Glimelius B., and Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol. 40 (2001) 340-360
23. Vecchione F., Fruscio R., Dell'Anna T., Garbi A., Garcia Parra R., Corso S., and Lissoni A.A. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer 17 (2007) 367-372
24. Bookman M.A. Developmental chemotherapy and management of recurrent ovarian cancer. J. Clin. Oncol. 21 (2003) 149s-167s
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
26. Andrisano V., Ballardini R., Hrelia P., Cameli N., Tosti A., Gotti R., and Cavrini V. Studies on the photostability and in vitro phototoxicity of Labetalol. Eur. J. Pharm. Sci. 12 (2001) 495-504
27. Hu W., and Kavanagh J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 4 (2003) 721-729
28. Armstrong J.S. Mitochondria: a target for cancer therapy. Br. J. Pharmacol. 147 (2006) 239-248
29. Arango D., Mariadason J.M., Wilson A.J., Yang W., Corner G.A., Nicholas C., Aranes M.J., and Auqenlicht L.H. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br. J. Cancer 89 (2003) 1757-1765
30. Ambrosini G., Seelman S.L., Qin L.X., and Schwartz G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res. 68 (2008) 2312-2320
31. Kim R., Emi M., and Tanabe K. Role of mitochondria as the gardens of cell death. Cancer Chemother. Pharmacol. 57 (2006) 545-553
32. Wood D.E., and Newcomb E.W. Cleavage of Bax enhances its cell death function. Exp. Cell Res. 256 (2000) 375-382
33. Wood D.E., and Newcomb E.W. Caspase-dependent activation of calpain during drug-induced apoptosis. J. Biol. Chem. 274 (1999) 8309-8315
34. Gao G., and Dou Q.P. N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome c release and apoptotic cell death. J. Cell. Biochem. 80 (2000) 53-72
35. 2-induced apoptosis of hepatocytes. Int. J. Mol. Med. 11 (2003) 369-374
36. Chipuk J.E., and Green D.R. Dissecting p53-dependent apoptosis. Cell death Differ. 13 (2006) 994-1002
37. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13 (2006) 921-926
38. Müller M., Scaffidi C.A., Galle P.R., Stremmel W., and Krammer P.H. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur. Cytokine Netw. 9 (1998) 685-686
39. Huang X., Kurose A., Tanaka T., Traganos F., Dai W., and Darzynkiewicz Z. Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine. Cancer Biol. Ther. 5 (2006) 959-964
40. Ikegami T., Matsuzaki Y., Al Rashid M., Ceryak S., Zhang Y., and Bouscarel B. Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. Mol. Cancer Ther. 5 (2006) 68-79
41. Wang P., Song J.H., Song D.K., Zhang J., and Hao C. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. Cell. Signal. 18 (2006) 1528-1535